Alar Pharmaceuticals (Taiwan) Performance
| 6785 Stock | TWD 146.00 3.50 2.34% |
The firm shows a Beta (market volatility) of -0.036, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Alar Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Alar Pharmaceuticals is likely to outperform the market. At this point, Alar Pharmaceuticals has a negative expected return of -0.32%. Please make sure to confirm Alar Pharmaceuticals' standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if Alar Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Alar Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Quick Ratio | 92.78 | |
| Fifty Two Week Low | 43.55 | |
| Fifty Two Week High | 55.10 |
Alar |
Alar Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 18,250 in Alar Pharmaceuticals on September 15, 2024 and sell it today you would lose (3,650) from holding Alar Pharmaceuticals or give up 20.0% of portfolio value over 90 days. Alar Pharmaceuticals is generating negative expected returns and assumes 2.6851% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Alar, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Alar Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alar Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alar Pharmaceuticals, and traders can use it to determine the average amount a Alar Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1186
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6785 |
Estimated Market Risk
| 2.69 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alar Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alar Pharmaceuticals by adding Alar Pharmaceuticals to a well-diversified portfolio.
Alar Pharmaceuticals Fundamentals Growth
Alar Stock prices reflect investors' perceptions of the future prospects and financial health of Alar Pharmaceuticals, and Alar Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alar Stock performance.
| Return On Equity | -10.38 | |||
| Return On Asset | -10.09 | |||
| Current Valuation | 2.47 B | |||
| Shares Outstanding | 57 M | |||
| Price To Book | 4.97 X | |||
| Revenue | 600 K | |||
| EBITDA | (100.27 M) | |||
| Cash And Equivalents | 556.12 M | |||
| Cash Per Share | 9.76 X | |||
| Total Debt | 1.07 M | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 10.50 X | |||
| Cash Flow From Operations | (71.85 M) | |||
| Earnings Per Share | (2.86) X | |||
About Alar Pharmaceuticals Performance
Evaluating Alar Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Alar Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alar Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Alar Pharmaceuticals Inc. operates as a drug development company. The company was founded in 2016 and is based in Taichung, Taiwan. ALAR PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 19 people.Things to note about Alar Pharmaceuticals performance evaluation
Checking the ongoing alerts about Alar Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alar Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alar Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the revenue of 600 K. Net Loss for the year was (64.78 M) with profit before overhead, payroll, taxes, and interest of 600 K. | |
| Alar Pharmaceuticals has accumulated about 556.12 M in cash with (71.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.76. |
- Analyzing Alar Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alar Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Alar Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alar Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alar Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alar Pharmaceuticals' stock. These opinions can provide insight into Alar Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Alar Stock Analysis
When running Alar Pharmaceuticals' price analysis, check to measure Alar Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alar Pharmaceuticals is operating at the current time. Most of Alar Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alar Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alar Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alar Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.